+181.4%
XLE vs MRNA
+878.5%
-697.1%
-63.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.0% | -3.6% | +1.7% | -1.9% |
| 7D | +2.8% | -20.0% | +22.8% | +2.9% |
| 30D | -6.7% | -1.3% | -5.4% | -6.7% |
| 3M | +3.5% | +240.0% | -236.5% | +2.0% |
| 6M | +8.6% | +339.0% | -330.4% | +6.4% |
| YTD | +45.3% | +630.0% | -584.7% | +40.6% |
| 1Y | +42.4% | +769.1% | -726.7% | +37.2% |
| 3Y | +68.8% | +181.2% | -112.4% | +64.5% |
| 5Y | +161.3% | -8.1% | +169.4% | +155.3% |
| All | +181.4% | +878.5% | -697.1% | +155.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling